AstraZeneca PLC
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Pascal Soriot D.V.M., M.B.A.
- Full Time Employees
- 89,900
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 1 Francis Crick Avenue Cambridge United Kingdom CB2 0AA
- IPO Date
- May 12, 1993
- CIK
- 0000901832
- Website
- astrazeneca.com
- Similar Companies
- Business
- AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Company News
Astrazeneca (AZN) Stock Falls Amid Market Uptick: What Investors Need to Know
Mindpeak to deploy and evaluate AI-Powered Digital Pathology Risk Assessment Tools for Breast Cancer in collaboration with AstraZeneca
AZN's Imfinzi Gets EU Nod for Limited-Stage Small-Cell Lung Cancer
AZN to Acquire EsoBiotec for $1B to Develop In Vivo Cell Therapies
IgniteData launches cutting edge data integration platform for clinical trials at Cambridge University Hospitals
AstraZeneca Buys EsoBiotec for Up to $1 Billion
AstraZeneca pays $1bn for biotech that may 'transform cell therapy'
AstraZeneca to buy Esobiotec for upto $1 billion
EsoBiotec to Be Acquired by AstraZeneca to Advance Cell Therapy Ambition
AstraZeneca and Erin Andrews team up to inspire fans to Get Body Checked Against Cancer
AstraZeneca Stock Nears Buy Point After Long Run In Declining Market
AstraZeneca experimental blood pressure drug has a good shot of becoming a blockbuster
AstraZeneca's Imfinzi success a step towards $80bn revenue aim - analyst
AstraZeneca's Imfinzi shows promise in early-stage stomach and oesophageal cancer
6 Ideal Buys From 14 'Safer' March Dividends On Bloomberg 2025 Watch List Of 50
AstraZeneca: A Big Pharma Blue Chip To Buy Now
2025 Endothelin Receptor Antagonist Pipeline Insights for 10+ Companies and 15+ Pipeline Drugs, Including Zibotentan (AstraZeneca), SC0062 (Biocity Biopharmaceutics), and GMA301 (Gmax Biopharm)
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 Trial
Positive results from the TEZSPIRE Phase III WAYPOINT trial highlight rapid and sustained effect in chronic rhinosinusitis with nasal polyps
Here's Why Astrazeneca (AZN) Gained But Lagged the Market Today